*Articles from the former Asklep
ASKLEP Inc., a Japan based CRO providing clinical research services and Qualitix Clinical Research Inc., a Taiwan CRO headquartered in Taipei, today announced the signing of a Strategic Partnership Agreement. The agreement means the two companies can offer their wide range of clinical research services to pharmaceutical, biotechnology and device companies in key territories, Taiwan and Japan.
ASKLEP and Qualitix both operate in key strategic regions of Asia and the relationship between the two companies now means that ASKLEP can support Japanese clients beyond the borders of Japan utilizing Qualitix’s high quality resources and local know-how.
In November, ASKLEP will be holding a Global Conference in Tokyo, and will focus on pharmaceutical R&D in key clinical development regions. Among the presenters for this conference will be ASKLEP (Japan), Qualitix (Taiwan), European partner, Harrison Clinical Research (http://www.harrisonclinical.com/) and North American partner ASKA Research (http://www.askaresearch.com/). If you wish to attend this global conference, kindly send email to the “contact us” link on this website.
Asklep, Inc., (http://www.asklep.co.jp) founded in 1992, in Tokyo, Japan, provides clinical research services in monitoring, data management, biostatistics, regulatory & consulting, CRA training, etc. ASKLEP is an INTAGE Group Company. INTAGE, INC., (http://www.intage.co.jp) is the largest marketing research company in Japan and the eleventh largest globally. It has one of the most comprehensive healthcare solution services in the industry
About Qualitix Clinical Research
Qualitix Clinical Research Co., Ltd. Qualitix is a full service CRO based in Taiwan and focuses on clinical monitoring and site management services for multinational phase II and phase III studies. Qualitix was established in June 2008; however, CRO business was commenced since 1997 under its parent company Genovate Biotechnology Co., Ltd. Qualitix plans to establish its presence in China by end of 2008 and expand its service area to China.